News for CareDx, Inc (CDNA)

CareDx, Inc. (Nasdaq: CDNA) ”“ The Transplant Companyâ„¢ focused on the discovery, development, and commercialization of clinically differentiated, high-value

CareDx, Inc. (CDNA) will announce its second quarter 2025 financial results on August 6, 2025. The company will host a conference call at 1:30 p.m. PT /

Shares of CareDx Inc (CDNA) surged 7.85% in mid-day trading on Jul 21. The stock reached an intraday high of $13.15, before settling at $12.85, up from its

In recent news regarding CareDx (CDNA), Craig-Hallum analyst Connor Chamberlain has maintained a "Buy" rating on the stock. However, the analyst has adjusted th

Key Takeaways: CareDx (CDNA) bounces back after addressing market concerns over its test products. Analysts provide strong upside potential with their price

Craig-Hallum has adjusted its price target for CareDx (CDNA), reducing it from $40 to $26, while maintaining a Buy rating on the stock. This revision comes afte

CareDx, Inc. (CDNA) announces a draft Local Coverage Determination (LCD) for solid organ transplant surveillance testing. The draft LCD confirms coverag

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow trade...

Shares of CareDx Inc (CDNA) fell 3.35% in mid-day trading on Jul 15. The stock reached an intraday low of $18.87, before recovering slightly to $19.35, down

On July 7, 2025, Peter Maag, a Director at CareDx Inc (CDNA), sold 10,000 shares of the company, as reported in a SEC Filing. Following this transaction, the in

Shares of CareDx Inc (CDNA) surged 8.06% in mid-day trading on Jul 9. The stock reached an intraday high of $20.91, before settling at $20.80, up from its p

CareDx (CDNA) has seen a positive shift in analyst sentiment, with Nephron Research's Thomas DeBourcy raising the stock's rating from Hold to Buy. DeBourcy set

Shares of CareDx Inc (CDNA) surged 3.87% in mid-day trading on Jul 2. The stock reached an intraday high of $19.68, before settling at $19.58, up from its p

On June 17, 2025, Peter Maag, Director at CareDx Inc (CDNA), sold 10,000 shares of the company. Following this transaction, the insider now owns 318,846 shares

Shares of CareDx Inc (CDNA) surged 9.75% in mid-day trading on Jun 4. The stock reached an intraday high of $19.75, before settling at $19.14, up from its p

CareDx (CDNA) completes a $50 million share buyback, representing 5% of its outstanding shares. Wall Street analysts project a significant upside potent

CareDx, Inc. (Nasdaq: CDNA), ”“ The Transplant Companyâ„¢ ”“ a leading precision medicine company focused on the discovery, development, and commercializatio

CareDx (CDNA) completes a $50 million share repurchase, approximately 5% of outstanding shares. The Board authorizes a new $50 million share repurchase

An important meeting hosted by Craig-Hallum focusing on CDNA is scheduled to take place in New York on June 6. This gathering is expected to provide significant